Physician profile
Jessica Singleton
NPI 1750857587
$6,274.95
in general payments reported to CMS, 2019-2025
28 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,050 · 2022: $2,200 · 2023: $654 · 2024: $1,131 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.53 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,614.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $787.41 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $571.79 | 2021-2023 | Farxiga, Lokelma |
| Dexcom, INC. | $453.79 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $397.36 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.12 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $277.79 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $256.36 | 2021-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $234.62 | 2021-2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $212.55 | 2021-2024 | |
| Medtronic, INC. | $160.98 | 2021-2024 | Minimed 780g, Intellis Adaptivestim |
| Amgen INC. | $148.18 | 2021-2022 | |
| Amarin Pharma, INC. | $145.13 | 2021 | |
| Zealand Pharma US, INC. | $99.35 | 2021 | |
| Abbott Laboratories | $88.63 | 2022-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $69.49 | 2021-2024 | |
| Abbvie INC. | $61.53 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $60.02 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Opko Pharmaceuticals, LLC | $47.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.11 | 2021-2022 | |
| Cequr Corporation | $30.34 | 2024 | Cequr Simplicity |
| Bigfoot Biomedical INC | $23.04 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $21.36 | 2025 | |
| Esperion Therapeutics, INC. | $18.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.25 | 2022 | |
| Sequel Med Tech, LLC | $17.89 | 2025 | Twiist |
| Pfizer INC. | $17.00 | 2022 | |
| Adlon Therapeutics L.P. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.